| Literature DB >> 26812110 |
Sandra Mara Burin1, Sandro Ghisla2, Amanda Tomie Ouchida3, Alexandre Ferro Aissa4, Maria Gabriela Berzoti Coelho5, Tássia Rafaella Costa6, Ana Paula Zambuzi Cardoso Marsola7, Belinda Pinto-Simões8, Lusânia Maria Greggi Antunes9, Carlos Curti10, Suely Vilela Sampaio11, Fabíola Attié de Castro12.
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Bcr-Abl tyrosine kinase protein, which confers resistance to apoptosis in leukemic cells. Tyrosine kinase inhibitors (TKIs) are effectively used to treat CML; however, CML patients in the advanced (CML-AP) and chronic (CML-CP) phases of the disease are usually resistant to TKI therapy. Thus, it is necessary to seek for novel agents to treat CML, such as the enzyme l-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) snake venom. We examined the antitumor effect of CR-LAAO in Bcr-Abl(+) cell lines and peripheral blood mononuclear cells (PBMC) from healthy subjects and CML patients. CR-LAAO was more cytotoxic towards Bcr-Abl(+) cell lines than towards healthy subjects' PBMC. The H2O2 produced during the enzymatic action of CR-LAAO mediated its cytotoxic effect. The CR-LAAO induced apoptosis in Bcr-Abl(+) cells, as detected by caspases 3, 8, and 9 activation, loss of mitochondrial membrane potential, and DNA damage. CR-LAAO elicited apoptosis in PBMC from CML-CP patients without TKI treatment more strongly than in PBMC from healthy subjects and TKI-treated CML-CP and CML-AP patients. The antitumor effect of CR-LAAO against Bcr-Abl(+) cells makes this toxin a promising candidate to CML therapy.Entities:
Keywords: Apoptosis; CR-LAAO; Calloselasma rhodostoma; Chronic myeloid leukemia; Tyrosine-kinase inhibitors; l-Amino acid oxidase
Mesh:
Substances:
Year: 2016 PMID: 26812110 DOI: 10.1016/j.ijbiomac.2016.01.069
Source DB: PubMed Journal: Int J Biol Macromol ISSN: 0141-8130 Impact factor: 6.953